In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284337 | PMC |
| http://dx.doi.org/10.1093/ofid/ofad240 | DOI Listing |
Publication Analysis
Top Keywords
mrna vaccines
8
vaccines symptomatic
8
infection ba5-dominant
8
ba5-dominant period
8
effectiveness ba1-
4
ba1- ba4/ba
4
ba4/ba 5-containing
4
5-containing bivalent
4
bivalent covid-19
4
covid-19 mrna
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!